



ASX / MEDIA RELEASE

ResApp to Present at Upcoming Investor Conferences in October

Brisbane, Australia, 10 October 2017 -- ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, today announced that members of the management team will present at the following upcoming investor conferences:

- ASX Spotlight Investor Conference on Thursday, October 12 at 10am (EDT) at the Convene Conference Centre in New York, USA;
- TechKnow Invest Roadshow on Tuesday, October 24 at 12:10pm (AEDT) at the Grand Hyatt Hotel in Melbourne, Victoria and on Thursday, October 26 at 11:25am (AEDT) at the Radisson Blu Hotel in Sydney, NSW; and
- Australia Biotech Invest 2017 on Tuesday, October 24 at 3:30pm (AEDT) at the Sofitel Melbourne on Collins in Melbourne, Victoria.

About ResApp Health Limited

ResApp Health Limited (ASX: RAP) is a digital health company developing smartphone applications for the diagnosis and management of respiratory disease. The technology is based on machine learning algorithms that use cough sounds to diagnose and measure the severity of respiratory conditions without the need for additional hardware. The algorithms were initially developed by The University of Queensland with funding from the Bill and Melinda Gates Foundation. ResApp has adult and paediatric clinical studies underway at leading US and Australian hospitals with results demonstrating accurate diagnosis of pneumonia, asthma/reactive airways disease, bronchiolitis, croup and upper respiratory tract infections in children as well as chronic obstructive pulmonary disease, asthma, pneumonia and upper respiratory tract infections in adults. Potential customers of ResApp's products include healthcare providers in telehealth, emergency department, urgent care and primary care settings as well as global aid and humanitarian organisations in the developing world.

For more information on ResApp, visit www.resapphealth.com.au

Contacts

Dr Tony Keating
CEO and Managing Director
+61 430 180 659
tony@resapphealth.com.au

Mr Brian Leedman
Executive Director and
Vice President, Corporate Affairs
+61 412 281 780
brian@resapphealth.com.au

ResApp Health Limited ABN 51 094 468 318

Headquarters: Level 8, 127 Creek St, Brisbane QLD 4000 Australia

Registered Office: Level 22, 44 St Georges Tce, Perth WA 6000 Australia

T +61 8 6211 5099 E info@resapphealth.com.au W www.resapphealth.com.au